Related Experiment Videos
De novo acute myeloid leukemia in patients with Crohn's disease
1Service Clinique des Maladies du Sang, Hôpital Saint Louis, Paris, France.
Insights
Crohn's disease (CD) is rarely linked to acute myeloid leukemia (AML). This study identified four AML cases in patients with prior CD, with three showing monoblastic AML, suggesting a potential association.
Area of Science:
- Hematology
- Gastroenterology
- Oncology
Background:
- Crohn's disease (CD) is an inflammatory bowel disease with occasional associations reported with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
- Understanding potential links between chronic inflammatory conditions and hematologic malignancies is crucial for patient management and risk assessment.
Observation:
- Four cases of AML were observed in patients with a prior history of Crohn's disease between 1991 and 1993.
- Three of these patients presented with specific subtypes of AML: AML4 and AML5, characterized by monoblastic proliferation.
Findings:
- Cytogenetic analysis in the AML patients revealed diverse results, including a normal karyotype, an inversion of chromosome 16 (inv(16)), and a deletion on chromosome 11 (del(11)(q24-25)).
- Notably, the three patients with AML4/AML5 had received limited prior immunosuppressive therapy for CD, with treatment durations ranging from 1 to 4 months.
Implications:
- The findings suggest a potential, albeit infrequent, association between Crohn's disease and the development of acute myeloid leukemia.
- Further research is warranted to elucidate the underlying mechanisms and confirm this association, potentially impacting surveillance strategies for CD patients.
Abstract:
Crohn's disease (CD) has been occasionally reported to be associated with myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML). From October 1991 to June 1993, four AML patients with a previous history of CD but no history of MDS were referred to our institution. Three presented AML with a monoblastic proliferation (one AML4 and two AML5). Cytogenetic analysis revealed a normal karyotype in two patients, an inv(16) in another and a del(11)(q24-25) in the fourth. Interestingly, the three patients with AML4/AML5 had not received high doses of immunosuppressive agents, prior CD therapy ranging from 1 to 4 months sulfasalazine with additional azathioprine in one case.